Selecting the second inhibitory target would highly depend on the type of the treated tumor, as different types of tumors were revealed to preferentially express certain co-inhibitory receptors (PD-L1, PD-L2, B7-H3, etc.). This evidence concerns the gene PDCD1LG2 and neoplasm.